Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company’s proprietary CombiPlex technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago.
The CombiPlex drug ratio [...]
Posted in Info | Tagged announces, cancer, celator, colorectal, cpx1, for, in, results, treatment, trial
Cinzia Designs announces the Top 5 Tips for protecting your eyes in style this summer. Each summer the Sun Safety Alliance designates a week to promote sun safety awareness.
According to the Vision Learning Center, many problems can occur from long-term exposure to UV rays including cataracts, macular degeneration, scaring, or skin cancer. These defects can [...]
Posted in Info | Tagged eyes, for, protecting, summer, this, Tips, your
Observational study explores Seroprotection against serogroup C meningococcal disease in 11-33 years olds in the United Kingdom and find that one in five adolescents aged 11-13 years appear to have inadequate protection against meningitis C and a booster dose of vaccine may therefore be needed to sustain protection amongst teenagers. The Seroprotection study is published [...]
Posted in Info | Tagged 20, c, factor, for, is, meningitis, of, percent, risk, teens
FDA announced a limited return of a reformulated heartworm prevention drug for dogs, which had been withdrawn because of serious, life-threatening adverse reactions, including loss of appetite, lethargy; vomiting, seizures, difficulty walking, jaundice (a yellowish appearance); and bleeding disorders, allergies, convulsions, followed in some cases by death.
ProHeart 6 (moxidectin) Sustained Release Injectable for Dogs, NADA [...]
Posted in Info | Tagged announces, dogs, drug, fda, for, heartworm, limited, of, return
Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine’s potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).
Results from the Phase II study (ASCO [...]
Posted in Info | Tagged a, adjuvant, as, for, highrisk, leukine, melanoma, patients, potential, therapy
EVIJO's blog